A new experimental drug made by Johnson & Johnson has demonstrated a better ability to lower blood sugar levels in patients with diabetes than Merck’s Januvia and the older, more conventional drug glimepiride, data from a couple of late-stage clinical trials of the drug have shown. Results of the studies, which were conducted over 52 weeks and involved more than 10,000 patients, also found the new Johnson & Johnson drug, canagliflozin, contributed to weight loss in patients better than Januvia and glimepiride (marketed as Amaryl and GLIMY) and was linked to fewer incidents of hypoglycemia, a dangerous drop in blood ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.